Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

Phase 3 Unknown 616 enrolled Zhejiang Cancer Hospital CSPC Ouyi Pharmaceutical Co., Ltd. · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, open-label phase III study. The treatment was compare the efficacy and safety of Albumin-bound Paclitaxel plus S-1 versus Oxaliplatin plus capecitabine (XELOX) treating stage Ⅲ gastric cancer as adjuvant setting

Timeline

Start: 2020-03-01
Primary completion: 2024-10-31
Completion: 2024-10-31

Publications

Cheng X, Wu D, Xu N, Chen L, Yan Z, Chen P, Zhou L, Yu J, Cui J, Li W, Wang C, Feng W, Wei Y, Yu P, Du Y, Ying J, Xu Z, Yang L, Zhang Y. Adjuvant albumin-bound paclitaxel combined with S-1 vs. oxaliplatin combined with capecitabine after D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase III multicenter, open-label, randomized controlled clinical trial protocol. BMC Cancer. 2021 Jan 12;21(1):56. doi: 10.1186/s12885-020-07772-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Capecitabine	Small molecule	1000 mg/m2	Oral
Comparator	Oxaliplatin	Small molecule	130 mg/m2	Intravenous
Subject	Paclitaxel	Small molecule	120 mg/m2	Intravenous
Subject	S-1	Small molecule	40 mg	Oral
Subject	S-1	Small molecule	50 mg	Oral
Subject	S-1	Small molecule	60 mg	Oral

Nab-paclitaxel Combined With S-1 as Adjuvant Chemotherapy for Stage Ⅲ Gastric Cancer

Summary

Timeline

Publications

Drugs

Indications